Clinical Trial Update: Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the CDK4/6 inhibitor abemaciclib in solid tumors with genetic alterations in D-type cyclins or amplification of CDK4/CDK6; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Cancer | Phase 2 | Status: RECRUITING